FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2993556900> ?p ?o ?g. }

• W2993556900 endingPage "S10" @default.
• W2993556900 startingPage "S10" @default.
• W2993556900 abstract "BACKGROUND: Vedolizumab (VDZ), a gut-selective monoclonal α4β7 integrin antibody, is approved for the treatment of moderately to severely active ulcerative colitis (UC) and Crohn’s disease. Intravenous (IV) VDZ was recently shown to be superior to subcutaneous (SC) adalimumab (ADA) in VARSITY (1), the first head-to-head randomized controlled trial (RCT) of biological therapies in UC. No comparative efficacy or safety data versus ADA exist for VDZ SC, a new formulation in development (2). To generate estimates of the comparative efficacy and safety of VDZ SC versus ADA, we conducted a network meta-analysis (NMA) of RCTs. METHODS: The NMA was conducted using results from a targeted literature review that identified RCTs of both VDZ and ADA: GEMINI 1, VISIBLE 1, ULTRA-2, and VARSITY. In the former two trials, responders were rerandomized at the end of induction, whilst the latter two trials were treat-through designs. To adequately analyze these trials in one network of evidence, efficacy outcomes were assessed conditionally upon response at start of maintenance. For treat-through studies, this was response at 6/8 weeks. Efficacy outcomes in the maintenance period were response and remission at 52/54 weeks. Safety outcomes were overall adverse events (AEs), serious AEs (SAEs), overall infections, serious infections, and AEs leading to discontinuation as reported at 52 weeks. Odds ratios (OR) with 95% credible intervals (CrI) were estimated using probit and binomial NMA models. ADA SC 40 mg Q2W, VDZ IV 300 mg Q4W, and VDZ IV 300 mg Q8W were all compared against VDZ SC 108 mg Q2W (reference group). RESULTS: ADA had lower rates for maintenance of response and remission relative to VDZ SC, but this was not statistically significant (ORs with 95% Crl: 0.60 [0.33, 1.08] and 0.59 [0.33, 1.09], respectively). Although overall AEs were significantly higher with ADA compared with VDZ SC (OR 2.02 [1.04, 3.89]), other safety outcomes were similar: overall infections, OR 1.86 (0.94, 3.77); serious AEs, OR 1.41 (0.54, 3.75); serious infections, OR 0.39 (0.05, 2.73); AEs leading to discontinuation, OR 2.58 (0.80, 9.44). As expected, VDZ IV had similar maintenance efficacy and safety outcomes relative to VDZ SC. CONCLUSION(S): Results from this indirect treatment comparison suggest that VDZ SC may achieve higher rates of maintenance response and remission among responders at start of maintenance than ADA and is associated with a lower risk of overall AEs. In the absence of a head-to-head trial between VDZ SC and ADA SC, these findings support a favorable benefit-risk profile of VDZ SC in UC." @default.
• W2993556900 created "2019-12-13" @default.
• W2993556900 creator A5005225915 @default.
• W2993556900 creator A5008693009 @default.
• W2993556900 creator A5020445619 @default.
• W2993556900 creator A5022482414 @default.
• W2993556900 creator A5022764809 @default.
• W2993556900 creator A5031295196 @default.
• W2993556900 creator A5045509681 @default.
• W2993556900 creator A5075986612 @default.
• W2993556900 date "2019-12-01" @default.
• W2993556900 modified "2023-09-26" @default.
• W2993556900 title "P038 Comparing the Efficacy and Safety of Subcutaneous Vedolizumab Versus Adalimumab for the Treatment of Ulcerative Colitis: A Network Meta-Analysis" @default.
• W2993556900 cites W2944465902 @default.
• W2993556900 doi "https://doi.org/10.14309/01.ajg.0000613120.28619.19" @default.
• W2993556900 hasPublicationYear "2019" @default.
• W2993556900 type Work @default.
• W2993556900 sameAs 2993556900 @default.
• W2993556900 citedByCount "0" @default.
• W2993556900 crossrefType "journal-article" @default.
• W2993556900 hasAuthorship W2993556900A5005225915 @default.
• W2993556900 hasAuthorship W2993556900A5008693009 @default.
• W2993556900 hasAuthorship W2993556900A5020445619 @default.
• W2993556900 hasAuthorship W2993556900A5022482414 @default.
• W2993556900 hasAuthorship W2993556900A5022764809 @default.
• W2993556900 hasAuthorship W2993556900A5031295196 @default.
• W2993556900 hasAuthorship W2993556900A5045509681 @default.
• W2993556900 hasAuthorship W2993556900A5075986612 @default.
• W2993556900 hasConcept C126322002 @default.
• W2993556900 hasConcept C141071460 @default.
• W2993556900 hasConcept C168563851 @default.
• W2993556900 hasConcept C197934379 @default.
• W2993556900 hasConcept C2776207728 @default.
• W2993556900 hasConcept C2778715236 @default.
• W2993556900 hasConcept C2779134260 @default.
• W2993556900 hasConcept C2780132546 @default.
• W2993556900 hasConcept C2780479503 @default.
• W2993556900 hasConcept C71924100 @default.
• W2993556900 hasConceptScore W2993556900C126322002 @default.
• W2993556900 hasConceptScore W2993556900C141071460 @default.
• W2993556900 hasConceptScore W2993556900C168563851 @default.
• W2993556900 hasConceptScore W2993556900C197934379 @default.
• W2993556900 hasConceptScore W2993556900C2776207728 @default.
• W2993556900 hasConceptScore W2993556900C2778715236 @default.
• W2993556900 hasConceptScore W2993556900C2779134260 @default.
• W2993556900 hasConceptScore W2993556900C2780132546 @default.
• W2993556900 hasConceptScore W2993556900C2780479503 @default.
• W2993556900 hasConceptScore W2993556900C71924100 @default.
• W2993556900 hasIssue "1" @default.
• W2993556900 hasLocation W29935569001 @default.
• W2993556900 hasOpenAccess W2993556900 @default.
• W2993556900 hasPrimaryLocation W29935569001 @default.
• W2993556900 hasRelatedWork W1996348078 @default.
• W2993556900 hasRelatedWork W2042655884 @default.
• W2993556900 hasRelatedWork W2587196664 @default.
• W2993556900 hasRelatedWork W2605674307 @default.
• W2993556900 hasRelatedWork W2997693921 @default.
• W2993556900 hasRelatedWork W3028093540 @default.
• W2993556900 hasRelatedWork W3167939738 @default.
• W2993556900 hasRelatedWork W4210933462 @default.
• W2993556900 hasRelatedWork W4226253339 @default.
• W2993556900 hasRelatedWork W4383388333 @default.
• W2993556900 hasVolume "114" @default.
• W2993556900 isParatext "false" @default.
• W2993556900 isRetracted "false" @default.
• W2993556900 magId "2993556900" @default.
• W2993556900 workType "article" @default.